Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
61 studies found for:    vedolizumab
Show Display Options
Rank Status Study
1 Recruiting Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab
2 Recruiting A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Condition: Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: Vedolizumab
3 Recruiting Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Condition: Colitis, Ulcerative
Intervention: Drug: Vedolizumab IV
4 Recruiting Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab
5 Withdrawn Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Interventions: Drug: Vedolizumab intravenous injection;   Drug: Vedolizumab subcutaneous injection
6 Not yet recruiting Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: Vedolizumab
7 Active, not recruiting An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: Vedolizumab
8 Not yet recruiting Defining Predictors of RT Response to Vedolizumab in IBD
Condition: Crohn Disease of Small Intestine
Intervention: Drug: Vedolizumab 300 MG Injection [Entyvio]
9 Recruiting Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Vedolizumab;   Drug: Placebo
10 Recruiting Dose Finding Study of Vedolizumab for Graft-Versus-Host Disease (GvHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Condition: Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: Vedolizumab
11 Not yet recruiting Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection
Condition: HIV-infection/AIDS
Intervention: Biological: Vedolizumab (brand name Entyvio)
12 Not yet recruiting Vedolizumab Induction May Prevent Celiac Enteritis
Condition: Celiac Disease
Intervention: Drug: Vedolizumab
13 Active, not recruiting Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: Vedolizumab
14 Recruiting Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
Conditions: Crohn's Disease;   Ulcerative Colitis;   Inflammatory Bowel Disease
Intervention: Drug: Vedolizumab
15 Completed
Has Results
Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
Condition: Healthy
Interventions: Drug: Vedolizumab SC;   Drug: Vedolizumab IV
16 Completed
Has Results
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: vedolizumab
17 Not yet recruiting Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
Condition: ULCERATIVE COLITIS
Interventions: Drug: VEDOLIZUMAB;   Drug: ADALIMUMAB
18 Recruiting Vedolizumab Subcutaneous Long-Term Open-Label Extension Study
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab SC
19 Active, not recruiting Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
20 Active, not recruiting Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.